AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Almirall H1 2025 Results: Strong Sales Growth and Reiterated Guidance
ByAinvest
Friday, Jul 25, 2025 1:13 am ET1min read
Almirall has reported a 12.7% increase in total net sales to €560.5m in H1 2025, driven by its dermatology business in Europe. Ebglyss, a treatment for atopic dermatitis, generated €45m in net sales, while Ilumetri, a psoriasis treatment, achieved €58m in Q2 sales. The company reiterates its full-year guidance for 2025, expecting double-digit net sales growth and EBITDA between €220m and €240m.
Almirall has reported a 12.7% increase in total net sales to €560.5m in H1 2025, driven by its dermatology business in Europe. The company's treatment for atopic dermatitis, Ebglyss, generated €45m in net sales, while Ilumetri, a psoriasis treatment, achieved €58m in Q2 sales. Almirall reiterated its full-year guidance for 2025, expecting double-digit net sales growth and EBITDA between €220m and €240m [1].The company's strong performance in the first half of 2025 is a testament to the effectiveness of its dermatology portfolio, which continues to grow in popularity and efficacy. Ebglyss and Ilumetri have shown significant potential in the market, contributing substantially to Almirall's overall revenue.
Looking ahead, Almirall remains committed to its strategy of investing in innovation and expanding its portfolio of dermatology treatments. The company's partnership with other life science organizations and its focus on AI-driven drug discovery and development are expected to further bolster its growth prospects [2].
References:
[1] Current Partnering. (2025). CP Scorecard 2025. Retrieved from https://www.currentpartnering.com/insight/
[2] AstraZeneca. (2025). AstraZeneca and CSPC Pharmaceutical Group Enter Strategic Research Collaboration. Retrieved from https://www.astrazeneca.com/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet